Search...
Cstone Pharmaceuticals to Present One of Its Autoimmune and Inflammation Pipeline Assets, CS2015 (OX40L/TSLP Bispecific Antibody
I'm PortAI, I can summarize articles.
CStone Pharmaceuticals will present its autoimmune and inflammation pipeline asset, CS2015 (OX40L/TSLP bispecific antibody), at the 2025 ACAAI Annual Scientific Meeting. This marks CS2015's first international academic presentation. The molecule targets OX40L and TSLP, showing potent inhibition of their signaling pathways and promising pharmacokinetic properties. CS2015 aims to treat various Th2 cell-mediated inflammatory diseases. The presentation will highlight its potential as a novel therapeutic agent for type 2 inflammation diseases.
Source: marketscreener The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments